RESEARCHERS DISCOVER HOW TO INHIBIT A KEY MECHANISM IN ALZHEIMER'S DISEASE

He Alzheimer's It is often thought of as a disease of the neurons: abnormal proteins accumulate, connections begin to fail, and, slowly, memory and other cognitive abilities fade away. However, the brain is not composed solely of neurons. It is crisscrossed by an extraordinary network of tiny blood vessels that keep that tissue alive, as well as by specialized cells that protect and stabilize that circulation. New research from the Icahn School of Medicine at Mount Sinai places precisely those vessels at the center of the story.

The main character is APOE4, a variant of the APOE gene known for decades to significantly increase the risk of Alzheimer’s disease. This does not mean that everyone who carries it will develop the disease, but its presence is the strongest known genetic risk factor for late-onset Alzheimer’s. The big question was how a genetic variant could trigger a cascade of events capable of ultimately damaging the brain.

The researchers constructed a cell-by-cell gene expression atlas of the blood vessels in the human brain and discovered a particularly troubling mechanism. APOE4 alters the behavior of cells called pericytes. These cells normally surround the small blood vessels, help stabilize them, and play a role in maintaining the blood-brain barrier—the biological boundary that regulates what can pass from the blood into brain tissue.

In the presence of APOE4, some of these pericytes begin to change. Instead of performing their normal protective function, they take on characteristics similar to those of cells that produce scar tissue. The result is fibrosis around the blood vessels and an increased accumulation of vascular amyloid.

That changes the way we view one aspect of the disease. The deterioration of blood vessels in the brain had long been considered, at least in part, a consequence of advanced Alzheimer's. The new study suggests that APOE4 It may actively contribute to that deterioration and become part of the process that drives the disease. But the most important experiment came later.

The researchers blocked a cellular signaling pathway known as TGF-β, related to tissue remodeling and fibrosis. In doing so, they were able to restore pericytic coverage around the blood vessels and reduce both scarring and the accumulation of vascular amyloid. The effect could also be replicated in aged mice carrying APOE4.

That is what makes this study far more significant than just another description of Alzheimer's disease. The researchers did not simply discover what was happening; they intervened in the mechanism and succeeded in reversing the effects of that damage in their experimental models.

The word “reverse,” however, requires context. No one has reversed Alzheimer’s in a person. The experiments do not show that blocking TGF-β It will not restore lost memory or halt the disease in patients. What was experimentally reversed was a vascular mechanism associated with APOE4. Turning that discovery into a safe therapy for humans will require much more research.

The second study, published at the same time, makes the story even more interesting.

The team used three-dimensional models of human brain tissue called “miBrains,” built from stem cells. They are not miniature human brains capable of thinking. They are complex experimental systems that bring together several of the brain’s major cell types, including neurons, glial cells, and blood vessel components. This makes it possible to observe interactions that are extremely difficult to study directly within a living human brain.

In those models, APOE4 This caused another problem. It led to an abnormal buildup of cholesterol in astrocytes, cells that are essential for maintaining the environment in which neurons function. This excess cholesterol affected the lysosomes, a kind of internal system for recycling and removing waste from the cell.

When that cleanup mechanism began to fail, the astrocytes had greater difficulty removing alpha-synuclein. This protein is best known for its association with the disease Parkinson's and Lewy body dementia. In the experiments, alpha-synuclein eventually accumulated and spread to the neurons.

Suddenly, APOE4 appears to be linked not only to amyloid and the blood vessels of the Alzheimer's, but rather with protein accumulation mechanisms involved in other neurodegenerative diseases.

The significance of both studies lies precisely in that convergence. For decades, we have classified Alzheimer’s, Parkinson’s, and other forms of dementia as distinct diseases, and clinically, they are. But the more deeply we examine the biology of the brain, the more shared processes emerge: inflammation, lipid metabolism, vascular function, the removal of cellular waste, and the accumulation of abnormal proteins.

This could have significant implications for the future of medicine. Instead of waiting until millions of neurons have been damaged and obvious symptoms appear, one strategy could be to identify much earlier which mechanisms are beginning to fail in a given person and take action to address them.

miBrains also offer a particularly interesting possibility. Mount Sinai is developing and preserving these tissues derived from patients’ cells. In the future, similar systems could make it possible to study how certain genetic variants affect a specific individual and to experimentally test potential interventions before translating them into clinical treatments. We are still a long way from that scenario.

But the discovery published today raises an important question. For a long time, knowing that APOE4 The fact that it increased the risk of Alzheimer's meant facing a threat without fully understanding how to stop it. Now, a much clearer chain of events is beginning to emerge: the gene alters certain cells, those cells damage the blood vessels, fibrosis increases, proteins accumulate, and the brain’s environment deteriorates. And when researchers interrupted one part of that chain, the process reversed. It is not a cure for Alzheimer's.

But for the first time, one of the mechanisms through which its primary genetic risk factor damages cerebral circulation appears not only as something we can observe, but also as something that, at least experimentally, we can begin to reverse.